Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 5/20 | 0.42 |
| ▸ | METAP2 | P50579 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15541079 | 0.88 | CHEK1 (0.50) | CHEK1MAPK10RIPK1NOS1METAP2 | |
| SCHEMBL4990505 | 0.76 | PIM3 (0.47) | MAPK10RIPK1PIM3 | |
| Indazole SCHEMBL4310146 | 0.73 | HSP90AA1 (0.68) | NOS1METAP2DYRK1AKDM4EMEN1 | |
| SCHEMBL22743873 | 0.71 | CHEK1 (0.39) | CHEK1MAPK10RIPK1NOS1METAP2 | |
| SCHEMBL26130820 | 0.71 | CHEK1 (0.42) | CHEK1MAPK10RIPK1NOS1METAP2 | |
| SCHEMBL10704493 | 0.69 | CA2 (0.49) | MAPK10RIPK1PIM3KDM4EMEN1 | |
| SCHEMBL22744430 | 0.69 | CHEK1 (0.40) | CHEK1MAPK10RIPK1NOS1METAP2 | |
| SCHEMBL29769140 | 0.69 | CHEK1 (0.58) | CHEK1NOS1METAP2DYRK1AKDM4E | |
| SCHEMBL8404434 | 0.69 | CHEK1 (0.58) | CHEK1NOS1METAP2DYRK1AKDM4E | |
| SCHEMBL9739358 | 0.68 | CA2 (0.43) | MAPK10RIPK1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | claimed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | claimed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | claimed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | CHEK1 798/4885MAPK10 2611/4885RIPK1 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.